Regression of metastatic, radiation/chemotherapy-resistant uterine serous carcinoma overexpressing HER2/neu with trastuzumab emtansine (TDM-1)
Background: The management of uterine-serous-carcinoma (USC) no longer amenable to treatment with surgery, radiation and/or chemotherapy remains dismal. Alternative therapeutic options are desperately needed. Case: We describe the case of a heavily pretreated 74-year-old patient with a recurrent USC...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2017-02-01
|
| Series: | Gynecologic Oncology Reports |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2352578916300881 |
| _version_ | 1818082347362287616 |
|---|---|
| author | Alessandro D. Santin Stefania Bellone Natalia Buza Peter E. Schwartz |
| author_facet | Alessandro D. Santin Stefania Bellone Natalia Buza Peter E. Schwartz |
| author_sort | Alessandro D. Santin |
| collection | DOAJ |
| description | Background: The management of uterine-serous-carcinoma (USC) no longer amenable to treatment with surgery, radiation and/or chemotherapy remains dismal. Alternative therapeutic options are desperately needed.
Case: We describe the case of a heavily pretreated 74-year-old patient with a recurrent USC overexpressing HER2/neu at 3+ level by IHC treated with the anti-HER2/neu antibody-drug-conjugate (ADC) trastuzumab-emtansine (TDM-1-Kadcyla-Genentech/Roche). She experienced a remarkable clinical response to TDM-1 with a complete resolution of a large metastatic, radiation/chemotherapy resistant tumor deposit in her abdominal wall muscle confirmed by multiple CAT scans and a prolonged systemic control of her disease.
Conclusion: TDM-1 may represent a novel treatment option for recurrent/metastatic HER2/neu-positive USC patients refractory to salvage-treatment. |
| first_indexed | 2024-12-10T19:20:39Z |
| format | Article |
| id | doaj.art-337356533549408f9b6a674891ca45a0 |
| institution | Directory Open Access Journal |
| issn | 2352-5789 |
| language | English |
| last_indexed | 2024-12-10T19:20:39Z |
| publishDate | 2017-02-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Gynecologic Oncology Reports |
| spelling | doaj.art-337356533549408f9b6a674891ca45a02022-12-22T01:36:29ZengElsevierGynecologic Oncology Reports2352-57892017-02-0119C101210.1016/j.gore.2016.12.003Regression of metastatic, radiation/chemotherapy-resistant uterine serous carcinoma overexpressing HER2/neu with trastuzumab emtansine (TDM-1)Alessandro D. Santin0Stefania Bellone1Natalia Buza2Peter E. Schwartz3Department of Obstetrics & Gynecology & Reproductive Sciences, Yale University School of Medicine, New Haven, CT 06520, United StatesDepartment of Obstetrics & Gynecology & Reproductive Sciences, Yale University School of Medicine, New Haven, CT 06520, United StatesDepartment of Pathology, Yale University School of Medicine, New Haven, CT 06520, United StatesDepartment of Obstetrics & Gynecology & Reproductive Sciences, Yale University School of Medicine, New Haven, CT 06520, United StatesBackground: The management of uterine-serous-carcinoma (USC) no longer amenable to treatment with surgery, radiation and/or chemotherapy remains dismal. Alternative therapeutic options are desperately needed. Case: We describe the case of a heavily pretreated 74-year-old patient with a recurrent USC overexpressing HER2/neu at 3+ level by IHC treated with the anti-HER2/neu antibody-drug-conjugate (ADC) trastuzumab-emtansine (TDM-1-Kadcyla-Genentech/Roche). She experienced a remarkable clinical response to TDM-1 with a complete resolution of a large metastatic, radiation/chemotherapy resistant tumor deposit in her abdominal wall muscle confirmed by multiple CAT scans and a prolonged systemic control of her disease. Conclusion: TDM-1 may represent a novel treatment option for recurrent/metastatic HER2/neu-positive USC patients refractory to salvage-treatment.http://www.sciencedirect.com/science/article/pii/S2352578916300881Uterine serous carcinomaTrastuzumab-emtansineHER2/neu |
| spellingShingle | Alessandro D. Santin Stefania Bellone Natalia Buza Peter E. Schwartz Regression of metastatic, radiation/chemotherapy-resistant uterine serous carcinoma overexpressing HER2/neu with trastuzumab emtansine (TDM-1) Gynecologic Oncology Reports Uterine serous carcinoma Trastuzumab-emtansine HER2/neu |
| title | Regression of metastatic, radiation/chemotherapy-resistant uterine serous carcinoma overexpressing HER2/neu with trastuzumab emtansine (TDM-1) |
| title_full | Regression of metastatic, radiation/chemotherapy-resistant uterine serous carcinoma overexpressing HER2/neu with trastuzumab emtansine (TDM-1) |
| title_fullStr | Regression of metastatic, radiation/chemotherapy-resistant uterine serous carcinoma overexpressing HER2/neu with trastuzumab emtansine (TDM-1) |
| title_full_unstemmed | Regression of metastatic, radiation/chemotherapy-resistant uterine serous carcinoma overexpressing HER2/neu with trastuzumab emtansine (TDM-1) |
| title_short | Regression of metastatic, radiation/chemotherapy-resistant uterine serous carcinoma overexpressing HER2/neu with trastuzumab emtansine (TDM-1) |
| title_sort | regression of metastatic radiation chemotherapy resistant uterine serous carcinoma overexpressing her2 neu with trastuzumab emtansine tdm 1 |
| topic | Uterine serous carcinoma Trastuzumab-emtansine HER2/neu |
| url | http://www.sciencedirect.com/science/article/pii/S2352578916300881 |
| work_keys_str_mv | AT alessandrodsantin regressionofmetastaticradiationchemotherapyresistantuterineserouscarcinomaoverexpressingher2neuwithtrastuzumabemtansinetdm1 AT stefaniabellone regressionofmetastaticradiationchemotherapyresistantuterineserouscarcinomaoverexpressingher2neuwithtrastuzumabemtansinetdm1 AT nataliabuza regressionofmetastaticradiationchemotherapyresistantuterineserouscarcinomaoverexpressingher2neuwithtrastuzumabemtansinetdm1 AT petereschwartz regressionofmetastaticradiationchemotherapyresistantuterineserouscarcinomaoverexpressingher2neuwithtrastuzumabemtansinetdm1 |